Flag of the European Union EU Clinical Trials Register Help

Clinical trials for Progression free survival

The European Union Clinical Trials Register   allows you to search for protocol and results information on:
  • interventional clinical trials that were approved in the European Union (EU)/European Economic Area (EEA) under the Clinical Trials Directive 2001/20/EC
  • clinical trials conducted outside the EU/EEA that are linked to European paediatric-medicine development

    • EU/EEA interventional clinical trials approved under or transitioned to the Clinical Trial Regulation 536/2014 are publicly accessible through the
    Clinical Trials Information System (CTIS).

    The EU Clinical Trials Register currently displays   44334   clinical trials with a EudraCT protocol, of which   7366   are clinical trials conducted with subjects less than 18 years old.   The register also displays information on   18700   older paediatric trials (in scope of Article 45 of the Paediatric Regulation (EC) No 1901/2006).

    Phase 1 trials conducted solely on adults and that are not part of an agreed paediatric investigation plan (PIP) are not publicly available (see Frequently Asked Questions ).  
     
    Examples: Cancer AND drug name. Pneumonia AND sponsor name.
    How to search [pdf]
    Search Tips: Under advanced search you can use filters for Country, Age Group, Gender, Trial Phase, Trial Status, Date Range, Rare Diseases and Orphan Designation. For these items you should use the filters and not add them to your search terms in the text field.
    Advanced Search: Search tools
     
    6,006 result(s) found for: Progression free survival. Displaying page 1 of 301.
    1  2  3  4  5  6  7  8  9  Next» Last»»
    EudraCT Number: 2005-003327-39 Sponsor Protocol Number: KKSH-14 Start Date*: 2006-04-21
    Sponsor Name:Martin-Luther-University
    Full Title: Integration of 3D-conformal, local radiotherapy (3DCRT) to metastatic sites in a paclitaxel weekly chemotherapy regimen in oligometastatic breast cancer patients: a phase I- and randomised phase II...
    Medical condition: oligometastatic breast cancer
    Disease:
    Population Age: Adults Gender: Female
    Trial protocol: DE (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2021-003542-21 Sponsor Protocol Number: ALADDIN Start Date*: 2022-02-28
    Sponsor Name:ARTIC - Association pour la Recherche de Thérapeutiques Innovantes en Cancérologie
    Full Title: Evaluation of dAroLutamide Addition to anDrogen Deprivation therapy and radIatioN therapy in newly diagnosed prostate cancer with pelvic lymph nodes metastases
    Medical condition: Prostate cancer with pelvic lymph nodes metastases.
    Disease:
    Population Age: Adults, Elderly Gender: Male
    Trial protocol: FR (Trial now transitioned)
    Trial results: (No results available)
    EudraCT Number: 2017-003189-29 Sponsor Protocol Number: ONCO-01-2017 Start Date*: 2018-02-09
    Sponsor Name:L'Institut Mutualiste Montsouris
    Full Title: A phase II/III multicentric randomized trial, compared abiraterone + dexamethasone versus standard abiraterone + prednisone in patients resistant-castration in metastatic prostate cancer
    Medical condition: Metastatic castration resistant prostate cancer patients under abiraterone + prednisone with exclusive biological progression (PSA progression on the PSAWG3 criteria)
    Disease: Version SOC Term Classification Code Term Level
    20.0 100000004864 10076506 Castration-resistant prostate cancer LLT
    Population Age: Adults, Elderly Gender: Male
    Trial protocol: FR (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2016-003031-38 Sponsor Protocol Number: GOIRC-05-2016 Start Date*: 2017-04-04
    Sponsor Name:GRUPPO ONCOLOGICO ITALIANO DI RICERCA CLINICA (GOIRC)
    Full Title: Phase II randomized study of maintenance Regorafenib vs Placebo in no progression patients after first-line platinum and fluoropyrimidines based chemotherapy in HER2 negative locally advanced/metas...
    Medical condition: No progression patients after first-line platinum and fluoropyrimidines based chemotherapy in HER2 negative locally advanced/metastatic gastric or gastroesophagel junction cancer
    Disease: Version SOC Term Classification Code Term Level
    21.1 100000004864 10071114 Metastatic gastric adenocarcinoma LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: IT (Completed)
    Trial results: (No results available)
    EudraCT Number: 2004-002295-41 Sponsor Protocol Number: PR2100 Start Date*: 2009-01-29
    Sponsor Name:The University of Birmingham
    Full Title: A randomised phase II/III study of Docetaxel plus Prednisolone vs. Docetaxel plus Prednisolone plus Zoledronic acid vs. Docetaxel plus Prednisolone plus Strontium-89 vs. Docetaxel plus Prednisolo...
    Medical condition: Hormone refractory Prostate Cancer (HRPC)
    Disease:
    Population Age: Adults, Elderly Gender: Male
    Trial protocol: GB (Completed)
    Trial results: View results
    EudraCT Number: 2010-021863-34 Sponsor Protocol Number: RHMCAN0739 Start Date*: 2011-02-10
    Sponsor Name:University Hospital Southampton NHS Foundation Trust
    Full Title: A phase II trial of the addition of ipilumimab to carboplatin and etoposide chemotherapy for the first line treatment of extensive small cell lung cancer
    Medical condition: Extensive stage small cell lung cancer
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: GB (Completed)
    Trial results: View results
    EudraCT Number: 2019-002991-15 Sponsor Protocol Number: SOLTI-1804 Start Date*: 2019-11-04
    Sponsor Name:SOLTI
    Full Title: HER2-PREDICT: Estudio Traslacional De Muestras De Tumor Procedentes De Los Ensayos Ds8201-A-U301 y Ds8201-A-U302
    Medical condition: Her2‑positive, unresectable and/or metastatic breast cancer.
    Disease:
    Population Age: Adults, Elderly Gender: Female
    Trial protocol: ES (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2017-001939-38 Sponsor Protocol Number: NIVINIHO Start Date*: 2018-04-18
    Sponsor Name:LYSARC
    Full Title: A prospective phase II study of nivolumab alone, or in combination with vinblastin in patients aged 61 years and older, with classical Hodgkin Lymphoma and coexisting medical conditions
    Medical condition: patients aged 61 years and older, with classical Hodgkin lymphoma and coexisting medical conditions
    Disease: Version SOC Term Classification Code Term Level
    20.1 100000004864 10080208 Classical Hodgkin lymphoma LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: FR (Completed) BE (Completed)
    Trial results: View results
    EudraCT Number: 2019-002400-40 Sponsor Protocol Number: FFCD1709 Start Date*: 2020-07-27
    Sponsor Name:Fédération Francophone de Cancérologie Digestive
    Full Title: A PROSPECTIVE, MULTICENTER, OPEN-LABEL, PHASE II STUDY TO EVALUATE EFFICACY AND SAFETY OF SELECTIVE INTERNAL RADIATION THERAPY PLUS XELOX, BEVACIZUMAB AND ATEZOLIZUMAB (IMMUNE CHEKPOINT INHIBITOR) ...
    Medical condition: MICROSATELLITE STABLE (MSS) COLORECTAL CANCER WITH LIVER-DOMINANT METASTASIS
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: FR (Trial now transitioned)
    Trial results: (No results available)
    EudraCT Number: 2014-000345-70 Sponsor Protocol Number: M12-914 Start Date*: 2014-07-01
    Sponsor Name:AbbVie Deutschland GmbH & Co. KG
    Full Title: A Phase III Randomized, Placebo-Controlled Trial of Carboplatin and Paclitaxel with or without the PARP Inhibitor Veliparib (ABT-888) in Her-2 Negative Metastatic or Locally Advanced Unresectable B...
    Medical condition: HER2-Negative Metastatic or Locally Advanced Unresectable BRCA-Associated mutation (BRCA1 and BRCA2) Breast Cancer
    Disease: Version SOC Term Classification Code Term Level
    19.0 100000004864 10027475 Metastatic breast cancer LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: FI (Completed) AT (Completed) SE (Prematurely Ended) GB (GB - no longer in EU/EEA) DK (Completed) PT (Completed) DE (Prematurely Ended) BE (Prematurely Ended) CZ (Completed) NO (Completed) HU (Prematurely Ended) IT (Prematurely Ended) NL (Completed) LV (Completed) ES (Prematurely Ended) FR (Prematurely Ended) LT (Completed) EE (Completed) PL (Prematurely Ended)
    Trial results: View results
    EudraCT Number: 2011-001938-42 Sponsor Protocol Number: UCL-ONCO2011-01 Start Date*: 2012-01-24
    Sponsor Name:Cliniques universitaires Saint-Luc
    Full Title: Randomized Phase II Study of CABAZITAXEL versus METHOTREXATE in patients with recurrent or metastatic squamous cell carcinoma of the head and neck previously treated with platinum-based therapy
    Medical condition: To evaluate the efficacy of cabazitaxel in patients with palliative head and neck previously treated with platinum-based therapy.
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: BE (Completed)
    Trial results: View results
    EudraCT Number: 2022-000082-41 Sponsor Protocol Number: 2021-0486 Start Date*: 2022-03-31
    Sponsor Name:Fundación para la Investigación en Urología
    Full Title: Impact of pitavastatin use in prostate cancer patients treated with new generation androgen therapy: multicenter clinical trial
    Medical condition: We propose a multicenter, prospective, randomized, single-blind clinical trial, without conflict of interest, to determine the clinical benefit of statins (Pitavastatin 2 mg) in prostate cancer pa...
    Disease:
    Population Age: Adults, Elderly Gender: Male
    Trial protocol: ES (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2014-004438-24 Sponsor Protocol Number: M14-483 Start Date*: 2015-06-23
    Sponsor Name:AbbVie Deutschland GmbH & Co. KG
    Full Title: INTELLANCE 2: ABT-414 alone or ABT-414 plus temozolomide versus lomustine or temozolomide for recurrent glioblastoma: a randomized phase II study of the EORTC Brain Tumor Group.
    Medical condition: Glioblastoma Multiforme For Pediatric - High Grade Glioma and DIPG
    Disease: Version SOC Term Classification Code Term Level
    20.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10018336 Glioblastoma PT
    20.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10018338 Glioma PT
    Population Age: Newborns, Infants and toddlers, Children, Adolescents, Under 18, Adults, Elderly Gender: Male, Female
    Trial protocol: NL (Completed) DE (Completed) HU (Completed) AT (Completed) FI (Completed) GB (Completed) IE (Completed) ES (Prematurely Ended) BE (Completed) CZ (Completed) FR (Completed) PL (Completed) IT (Completed)
    Trial results: View results
    EudraCT Number: 2019-004388-37 Sponsor Protocol Number: 69HCL19_0457 Start Date*: 2020-03-03
    Sponsor Name:Hospices Civils de Lyon
    Full Title: A Three-Cohort Phase II trial to Assess the Efficacy of a Maintenance Treatment with TALAzoparib following First Line Platinum-based Chemotherapy in Pleural and Malignant Peritoneal MESOthelioma Pa...
    Medical condition: This study involves adults subjects with advanced malignant pleural (cohort A) or peritoneal (cohorts B1 and B2) mesothelioma. The cohorts B1 will be patient populations with non-resected or incomp...
    Disease: Version SOC Term Classification Code Term Level
    21.0 100000004864 10035605 Pleural mesothelioma malignant advanced LLT
    21.0 100000004864 10034669 Peritoneal mesothelioma malignant advanced LLT
    Population Age: Adults Gender: Male, Female
    Trial protocol: FR (Trial now transitioned)
    Trial results: (No results available)
    EudraCT Number: 2018-002767-26 Sponsor Protocol Number: LyRICX Start Date*: 2019-06-25
    Sponsor Name:Academic Medical Center
    Full Title: Liposomal iRInotecan, Carboplatin or oXaliplatin in the first line treatment of esophagogastric cancer: a randomized phase 2 study (LyRICX)
    Medical condition: gastroesophageal cancer
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: NL (Trial now transitioned)
    Trial results: (No results available)
    EudraCT Number: 2020-005141-16 Sponsor Protocol Number: NL75539.078.20 Start Date*: 2021-06-23
    Sponsor Name:Erasmus MC
    Full Title: Perioperative versus adjuvant FOLFIRINOX for resectable pancreatic cancer: the PREOPANC-3 study.
    Medical condition: non-metastatic resectable pancreatic cancer
    Disease: Version SOC Term Classification Code Term Level
    21.0 100000004864 10033602 Pancreatic adenocarcinoma resectable LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: NL (Trial now transitioned)
    Trial results: (No results available)
    EudraCT Number: 2016-000547-14 Sponsor Protocol Number: BGOG-cx3 Start Date*: 2017-08-30
    Sponsor Name:BGOG-UZLeuven
    Full Title: BGOG-cx3: Prospective randomized Phase II trial comparing doxorubicin alone versus doxorubicin and atezolizumab in recurrent cervical cancer
    Medical condition: recurrent cervical cancer
    Disease: Version SOC Term Classification Code Term Level
    21.1 100000004864 10065147 Malignant solid tumor LLT
    Population Age: Adults, Elderly Gender: Female
    Trial protocol: BE (Completed)
    Trial results: (No results available)
    EudraCT Number: 2016-003996-23 Sponsor Protocol Number: SAKK08/16 Start Date*: 2017-08-29
    Sponsor Name:SAKK
    Full Title: ODM-201 maintenance therapy in patients with metastatic castration resistant prostate cancer (mCRPC) previously treated with one novel hormonal agent first line and nonprogressive disease after sec...
    Medical condition: Metastatic castration resistant prostate cancer
    Disease: Version SOC Term Classification Code Term Level
    20.0 100000004864 10007453 Carcinoma of the prostate metastatic LLT
    Population Age: Adults, Elderly Gender: Male
    Trial protocol: IT (Prematurely Ended) ES (Ongoing) FR (Prematurely Ended)
    Trial results: (No results available)
    EudraCT Number: 2005-003021-19 Sponsor Protocol Number: BCPP2005-01 Start Date*: 2006-08-22
    Sponsor Name:University Of Birmingham
    Full Title: The use of selenium and vitamin E supplementation to prevent recurrence and progression of non-muscle-invasive bladder cancer
    Medical condition: Non-muscle-invasive transitional cell carcinoma of the bladder
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: GB (GB - no longer in EU/EEA)
    Trial results: (No results available)
    EudraCT Number: 2013-002973-23 Sponsor Protocol Number: GAP Start Date*: 2013-11-07
    Sponsor Name:Fondazione GISCAD
    Full Title: A Phase II randomized trial comparing a combination of Abraxane and Gemcitabine versus Gemcitabine alone as first line treatment in locally advanced unresectable pancreatic cancer.
    Medical condition: 124 locally advanced unresectable pancreatic cancer patients will be randomized in a 1:1 ratio to receive abraxane/gemcitabine (arm A) or gemcitabine alone (arm B), as first-line chemotherapy
    Disease:
    Population Age: Adults Gender: Male, Female
    Trial protocol: IT (Ongoing)
    Trial results: (No results available)
    Download Options:
    Number of Trials to download:
    Download Content:
    Download Format:
    Note, where multi-state trials are shown in search results, selecting "Full Trial details" will download full information for each of the member states/countries involved in the trial.
    1  2  3  4  5  6  7  8  9  Next» Last»»
    Query did not match any studies.
    For support, Contact us.
    The status and protocol content of GB trials is no longer updated since 1 January 2021. For the UK, as of 31 January 2021, EU Law applies only to the territory of Northern Ireland (NI) to the extent foreseen in the Protocol on Ireland/NI. Legal notice
    As of 31 January 2023, all EU/EEA initial clinical trial applications must be submitted through CTIS . Updated EudraCT trials information and information on PIP/Art 46 trials conducted exclusively in third countries continues to be submitted through EudraCT and published on this website.

    European Medicines Agency © 1995-Thu May 01 02:20:51 CEST 2025 | Domenico Scarlattilaan 6, 1083 HS Amsterdam, The Netherlands
    EMA HMA